Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating
Ilija Uzelac1, Shahriar Iravanian2, Hiroshi Ashikaga3
1School of Physics, Georgia Institute of Technology, Atlanta, Georgia.
Insights
Hydroxychloroquine (HCQ) can cause dangerous heart rhythm problems. This study found HCQ increases action potential dispersion and triggers ventricular tachycardia, highlighting its proarrhythmic effects.
Area of Science:
- Cardiovascular pharmacology
- Electrophysiology
- Drug safety
Background:
- Hydroxychloroquine (HCQ) was widely investigated for COVID-19 treatment.
- Concerns exist regarding HCQ's effectiveness and proarrhythmic potential, particularly QT prolongation.
Purpose of the Study:
- To investigate the specific arrhythmic effects of HCQ.
- To assess HCQ's cardiac risks in a population (COVID-19 patients) already prone to arrhythmias.
Main Methods:
- Utilized optical mapping with voltage-sensitive dyes.
- Examined ex vivo guinea pig and rabbit hearts.
- Perfused hearts with the upper therapeutic serum dose of HCQ (1000 ng/mL).
Main Results:
- HCQ significantly increased action potential dispersion.
- Repolarization alternans were observed.
- Polymorphic ventricular tachycardia was initiated by HCQ.
Conclusions:
- The study confirms the proarrhythmic effects of hydroxychloroquine.
- Findings underscore the cardiac risks associated with HCQ use.
Background:
Early during the current coronavirus disease 19 (COVID-19) pandemic, hydroxychloroquine (HCQ) received a significant amount of attention as a potential antiviral treatment, such that it became one of the most commonly prescribed medications for COVID-19 patients. However, not only has the effectiveness of HCQ remained questionable, but mainly based on preclinical and a few small clinical studies, HCQ is known to be potentially arrhythmogenic, especially as a result of QT prolongation.
Objective:
The purpose of this study was to investigate the arrhythmic effects of HCQ, as the heightened risk is especially relevant to COVID-19 patients, who are at higher risk for cardiac complications and arrhythmias at baseline.
Methods:
An optical mapping technique utilizing voltage-sensitive fluorescent dyes was used to determine the arrhythmic effects of HCQ in ex vivo guinea pig and rabbit hearts perfused with the upper therapeutic serum dose of HCQ (1000 ng/mL).
Results:
HCQ markedly increased action potential dispersion, resulted in development of repolarization alternans, and initiated polymorphic ventricular tachycardia.
Conclusion:
The study results further highlight the proarrhythmic effects of HCQ.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers


